SYRE Stock Analysis: Buy, Sell, or Hold?
SYRE - Spyre Therapeutics, Inc. Common Stock
$106.49
-1.30 (-1.21%)
▼
5d:
+2.76%
30d:
+6.5%
90d:
+43.29%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When SYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SYRE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SYRE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SYRE is currently trading at $106.49, which is considered extended relative to its 30-day fair value range of $98.54 to $105.84.
Technical Outlook: Technically, SYRE is in a strong uptrend. Immediate support is located at $95.61, while resistance sits at $110.17.
Market Sentiment: SYRE scores 19/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $124.71 (+14.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SYRE is in a strong uptrend. Immediate support is located at $95.61, while resistance sits at $110.17.
Market Sentiment: SYRE scores 19/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $124.71 (+14.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$98.54 -
$105.84
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
23.7%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (19/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($124.71)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$98.54 -
$105.84
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$95.61
Resistance Level
$110.18
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-31.63
Wall Street Target
$124.71
(+14.5%)
Earnings Growth (YoY)
-99.7%
Share & Embed Analysis
Last updated: August 23, 2026 5:50 AM ET
Data refreshes hourly during market hours. Next update: 6:50 AM
Data refreshes hourly during market hours. Next update: 6:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Cameron Turtle
SELL
15000 shares
2026-04-01
Scott L Burrows
SELL
7500 shares
2026-04-01
Sheldon Sloan
SELL
7958 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
